» Articles » PMID: 9619596

Expression of Facilitative Glucose Transporter Isoforms in Lung Carcinomas: Its Relation to Histologic Type, Differentiation Grade, and Tumor Stage

Overview
Journal Mod Pathol
Specialty Pathology
Date 1998 Jun 10
PMID 9619596
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Expression of facilitative glucose transporter (Glut) isoforms was studied immunohistochemically in lung carcinomas. Glut-1 was expressed in 45 (74%) of 61 lung carcinomas, including 19 (100%) of 19 squamous cell carcinomas. No Glut-1 staining was seen in normal lung epithelium surrounding the tumors. In squamous cell carcinomas and small cell carcinomas, Glut-1 immunostaining was stronger in the central area of tumor cell nests corresponding to the hypoperfused region. Focal staining was seen in 14 (58%) of 24 adenocarcinomas, and positive staining was correlated to lesser differentiation, larger tumor size, and positive lymph node metastasis. Glut-2 was detected in normal airway epithelium, but no positive staining was seen in lung carcinomas. Glut-3 and Glut-4 were not positively stained in normal lung epithelia, but a few lung carcinoma samples showed positive reaction (9 of 61 in Glut-3; 4 of 61 in Glut-4). Glut-4 immunoexpression was seen in regenerating alveolar and bronchiolar epithelia around and in cancer tissues. Glut-5 expression was not detected in normal and tumor tissues. Reverse transcriptase-polymerase chain reaction for Glut-1, Glut-3, and Glut-4 confirmed the expression revealed by immunohistochemical analysis. Overexpression of Glut could enhance uptake of glucose into lung carcinoma cells, and the increased glucose influx could be involved in cell biologic activities.

Citing Articles

The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma.

Kokeza J, Strikic A, Ogorevc M, Kelam N, Vukoja M, Dilber I Int J Mol Sci. 2023; 24(13).

PMID: 37445752 PMC: 10341668. DOI: 10.3390/ijms241310575.


Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.

Ren C, Wang Q, Wang S, Zhou H, Xu M, Li H Front Endocrinol (Lausanne). 2023; 14:1148117.

PMID: 37033267 PMC: 10080042. DOI: 10.3389/fendo.2023.1148117.


as diagnostic markers and therapeutic targets in LUAD patients through bioinformatic analysis.

Zhang Y, Qin H, Bian J, Ma Z, Yi H Front Pharmacol. 2022; 13:1045179.

PMID: 36518662 PMC: 9742449. DOI: 10.3389/fphar.2022.1045179.


Value of F FDG-PET/CT parameters on long term follow-up for patients with non-small cell lung cancer.

Zoair M, Taber S, Bittner R, Foerster G, Griff S, Bauer T Innov Surg Sci. 2022; 7(2):35-43.

PMID: 36317010 PMC: 9574653. DOI: 10.1515/iss-2022-0009.


Glucose transporters as markers of diagnosis and prognosis in cancer diseases.

Szablewski L Oncol Rev. 2022; 16(1):561.

PMID: 35340885 PMC: 8941341. DOI: 10.4081/oncol.2022.561.